title: Analysis of genetic aberrations on chromosomal region 8q21-24 identifies E2F5 as an oncogene with copy number gain in prostate cancer.
abstract: The copy number gain of genes in chromosomal region 8q21-24 has been demonstrated to be associated with genesis and progression of prostate cancer (PCa). The aim of this study was to identify novel and effective molecular markers in this chromosomal region for PCa. The differentially expressed genes in PCa specimens were screened by gene microarray analysis, which was validated by RT-QPCR analysis. Then, the DNA qPCR analysis was carried out to detect the copy number changes of these differentially expressed genes. Moreover, the clinical significance of candidate markers (MYC and E2F5) in PCa were further determined. E2F5 and MYC were identified as candidate markers in PCa tissues and PCa cell lines. The DNA qPCR revealed the significant copy number gains of E2F5 and MYC in PCa tissues but not in PCa cell lines. In addition, Western blot analysis and immunohistochemical staining both found the significant higher expression of E2F5 and MYC proteins in PCa tissues than those in adjacent benign specimens (all P < 0.01). Moreover, the overexpression of E2F5 protein was significantly associated with a high Gleason score (P < 0.01), an advanced clinical stage (P = 0.01), a positive metastasis (P < 0.01) and PSA Failure (P < 0.01). The overexpression of MYC was more frequently found in PCa tissues with positive metastasis (P = 0.02) and PSA failure (P = 0.02). Interestingly, there was a close correlation in the expression level of MYC in PCa tissues with that of E2F5 (r ( s ) = 0.5, P ≤ 0.001). Our data offers the convincing evidence that the copy number gains of E2F5 and MYC may play an important role in genesis and progression of PCa. Especially, E2F5 may be a novel potential candidate marker for malignant PCa.
authors: State Key Lab of Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510120, China.
authors: Jin
authors: J
authors: Zhao
authors: Xin-Yang
authors: XY
authors: Wu
authors: Xiao-Hui
authors: XH
authors: Ling
authors: Zhuo-Yuan
authors: ZY
authors: Lin
authors: Xin
authors: X
authors: Fu
authors: Ye-Han
authors: YH
authors: Deng
authors: Hui-Chan
authors: HC
authors: He
authors: Weide
authors: W
authors: Zhong
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000235:genetics*; D015153:Blotting, Western; D045744:Cell Line, Tumor; D002869:Chromosome Aberrations; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics*; D050700:E2F5 Transcription Factor / Q000235:genetics*; D018628:Gene Dosage; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D020411:Oligonucleotide Array Sequence Analysis; D016274:Oncogene Protein p55(v-myc) / Q000235:genetics; D015513:Oncogene Proteins / Q000235:genetics*; D011471:Prostatic Neoplasms / Q000235:genetics*; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D014408:Biomarkers, Tumor; D050700:E2F5 Transcription Factor; C092558:E2F5 protein, human; D016274:Oncogene Protein p55(v-myc); D015513:Oncogene Proteins
references: Eur Urol. 2007 Jul;52(1):116-25
references: 17070983
references: Breast Cancer Res. 2003;5(6):R187-98
references: 14580254
references: Mol Cell Biol. 1999 Dec;19(12):8442-50
references: 10567569
references: Cancer Cell. 2010 Jul 13;18(1):11-22
references: 20579941
references: Proc Natl Acad Sci U S A. 2010 May 25;107(21):9742-6
references: 20453196
references: Virchows Arch. 2011 Feb;458(2):197-203
references: 21113617
references: Med Oncol. 2012 Sep;29(3):1972-84
references: 22038724
references: Med Oncol. 2012 Dec;29(4):2877-88
references: 22215415
references: Nat Rev Mol Cell Biol. 2002 Jan;3(1):11-20
references: 11823794
references: Br J Cancer. 2007 Feb 12;96(3):499-506
references: 17245344
references: BMC Cancer. 2010 Aug 27;10:460
references: 20799942
references: Clin Cancer Res. 2007 Jan 1;13(1):144-51
references: 17200349
references: Nat Genet. 2011 Jul 10;43(8):785-91
references: 21743467
references: Cancer Genet Cytogenet. 2003 Feb;141(1):56-64
references: 12581899
references: Eur Urol. 2002 Mar;41(3):328-34
references: 12180237
references: Genes Chromosomes Cancer. 2000 May;28(1):126-30
references: 10738311
references: Prostate Cancer Prostatic Dis. 2010 Sep;13(3):238-43
references: 20634801
references: Mol Cell. 2002 Jul;10(1):7-8
references: 12150900
references: Cancer Res. 2004 Jun 1;64(11):3814-22
references: 15172988
references: Eur J Cancer. 2005 Apr;41(6):858-87
references: 15808955
references: Cell. 2002 Jul 12;110(1):19-32
references: 12150994
references: Br J Cancer. 2009 Mar 10;100(5):764-71
references: 19259095
references: Cancer Res. 2007 Sep 1;67(17):8229-39
references: 17804737
references: Genes Cancer. 2010 Jun;1(6):617-28
references: 21779461
references: Mod Pathol. 2008 Sep;21(9):1156-67
references: 18567993
references: Int J Cancer. 2012 Jan 15;130(2):300-8
references: 21328337
references: Cancer Res. 2009 Jul 1;69(13):5568-74
references: 19549893
references: Genes Chromosomes Cancer. 2000 Jan;27(1):95-103
references: 10564591